A5030414104- Lymphoma Diagnosis and Treatment
- Lung Cancer Diagnosis and Treatment
- CAR-T cell therapy research
- Chronic Lymphocytic Leukemia Research
- Lung Cancer Treatments and Mutations
- Multiple Sclerosis Research Studies
- Esophageal Cancer Research and Treatment
- Biosimilars and Bioanalytical Methods
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Cancer Immunotherapy and Biomarkers
- Statistical Methods in Clinical Trials
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Rheumatoid Arthritis Research and Therapies
- Statistical Methods and Inference
- Colorectal and Anal Carcinomas
- Cancer Diagnosis and Treatment
- CNS Lymphoma Diagnosis and Treatment
- Peripheral Neuropathies and Disorders
- Health Systems, Economic Evaluations, Quality of Life
- Head and Neck Cancer Studies
- Global Cancer Incidence and Screening
Roche (Switzerland)
2022-2025
Mayo Clinic in Arizona
2023
AbbVie (United States)
2023
University of Utah
2023
The National Institute for Health and Care Excellence (England's health technology assessment body) recommend the use of average treatment effect (ATE) as an estimand economic evaluations. However there is limited literature on methods to estimate ATE, particularly in case survival outcomes. Single-arm trials real-world data are playing increasing role assessments, oncology/rare diseases, generating a need new ATE estimation methods. This study aimed present adaptation utility this...
Fixed-treatment duration glofitamab and treat-to-progression epcoritamab are approved in the US for diffuse large B-cell lymphoma (DLBCL) after ≥2 prior therapies. An economic model was developed to estimate per-patient total cost of care (TCC) versus from a healthcare perspective. Treatment costs were based on time-to-off-treatment (glofitamab, NCT03075696) progression-free survival (epcoritamab, NCT03625037). Per-patient savings, adjusted 2023 dollars, observed with across cycles 1-3...
Mosunetuzumab has received accelerated approval by the US Food and Drug Administration for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two more lines of systemic therapy. We evaluated cost-effectiveness mosunetuzumab treatment R/R FL from a private payer perspective.
Atezolizumab monotherapy has marketing authorisation by the Medicines and Healthcare products Regulatory Agency as adjuvant treatment following complete resection for adults with stage II-IIIA non-small cell lung cancer (NSCLC) whose tumours have PD-L1 expression on ≥ 50% of tumour cells disease not progressed platinum-based chemotherapy. This study evaluated cost-effectiveness atezolizumab vs best supportive care (BSC) in licensed patient population from a UK perspective.Patient...
Multiple sclerosis (MS) is a progressively debilitating neurologic disease that poses significant costs to the healthcare system and workforce.To evaluate impact of MS progression on societal quality life (QoL) using data from German NeuroTransData (NTD) registry.Cross-sectional cohort study. The cost included patients with disability assessed Expanded Disability Status Scale (EDSS) in 2019 while QoL EDSS EuroQol-5 Dimension 5-Levels between 2009 2019. Direct indirect medical, non-medical...
Understanding the socioeconomic burden of multiple sclerosis (MS) is essential to inform policymakers and payers. Real-world studies have associated increasing costs worsening quality life (QoL) with disability progression. This study aims further evaluate impact cognition, fatigue, upper lower limb function (ULF, LLF) impairments, disease progression per Expanded Disability Status Scale (EDSS) level, on QoL. was a cross-sectional cohort including 20,988 patients from German NeuroTransData...